Drug Development Technology: Frost & Sullivan Award goes to Imperacer

03-Nov-2008 - The 2008 European Immunoassay Frost & Sullivan Excellence in Technology Award has been awarded to Chimera Biotec. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunosorbent ...

Extensive Proteomics Research Strengthens the Uptake for Protein Purification Kits in Europe

05-Dec-2007 - The growing need for the production of more proteins within faster timelines is forcing laboratories to look for better expression systems and automated solutions to meet their demands. This increasing need to identify and understand proteins is driving the research and growth in the European ...

Surge in Strategic Alliances and Licensing Deals to Boost Productivity of Pharmaceutical Companies

12-May-2006 - A steep decline in innovation levels, combined with the threat from generics and drug recalls is causing concern to several pharmaceutical companies. As a result, pharmaceutical companies across the world are collaborating with biotech companies, thus relying on external resources to boost their ...

Bioinformatics Market Surges Ahead

Data Proliferation and Need for Improved Drug Research Productivity Underline Appeal of Bioinformatics

25-Aug-2005 - Efforts to effectively manage the flood of genetic and protein data being generated, the pressing need to boost drug research productivity together with solid government support are driving the European bioinformatics industry. With the quantity of genetic and protein data reaching peta bytes ...

Genomics and Proteomics to Increase the Efficiency of Drug Discovery and Development

07-Apr-2005 - While the United States is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to ...

Frost & Sullivan: Escalating Demand for Novel and Effective Therapeutic Approaches Underlines Growing Appeal of Peptides

Strategic Analysis of the Therapeutic Peptides Market in Europe

14-Jan-2005 - With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is ...

Time and Cost Savings Promote Appeal of High Throughput Screening in Drug Discovery

Strategic Analysis of European High Throughput Screening Market

27-Oct-2004 - Pharmaceuticals and biotechnology companies are under constant pressure to discover and develop new therapeutics at a lesser cost and within shorter timeframes. However, with investments exceeding USD 500 million and nine out of ten candidates failing to get drug approval, pharmaceuticals and ...

Emerging Technologies in Lab-on-a-Chip: Microfluidics and µTAS

Key Developments in Microfluidics and µTAS Accelerates the Commercial Acceptance of Lab-on-a-chip Technology

30-Sep-2004 - London, UK. Lab-on-a-chip (LOC) development has skyrocketed in the last couple of years due to constant efforts in harnessing microfluidics and µTAS to improve the LOC design and function. The distinct advantages that they bestow on applications are pushing the commercial potential of ...

Biochip Technology to Revolutionise the Pharmaceutical Industry

17-May-2004 - Advancements in biotechnology have culminated in its integration with semiconductor technologies such as micro-electromechanical systems, resulting in the evolution of biochips. Biochips provide pharma companies with sophisticated tools for speedy development of drugs and accurate diagnosis and ...

European Governments Hold the Key to Growth of Laboratory Software and Systems Market

LIMS/LIS Market and POCT Supplement

20-Feb-2004 - London, UK - Fuelled by the coincidence of vendor and end-user objectives of improved enterprise connectivity, the EUR172.3-million European laboratory software and systems market has entered a period of dynamic change. Budgetary myopia, however, looms as a key obstacle to exploiting potential ...